Complete this form to receive corporate updates and further details on how to invest in Albert Labs. By completing this form, you agree to our privacy policy.
Click here to access our investor documents
Corporate Highlights
First biopharmaceutical company leveraging established, accelerated pathways to psychedelic-assisted therapies for patients with urgent, unmet needs across the UK, EU and other healthcare networks
Developing scalable solutions to generate clinical data through access to existing patient pools within world-leading research and clinical networks
Initial focus on treating cancer-related anxiety and depression before moving into broader mental health indicationsÂ